A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

NCT04927884 PHASE1, PHASE2 TERMINATED Results posted

This is a phase 1b/2 open-label study to evaluate the safety and efficacy of sacituzumab govitecan-hziy in combination with chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK) in subjects with Triple Negative Breast Cancer (TNBC) after at least 2 prior treatments for metastatic disease.

Details

Lead sponsor	ImmunityBio, Inc.
Phase	PHASE1, PHASE2
Status	TERMINATED
Enrolment	3
Start date	Wed Sep 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Dec 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Advanced Triple Negative Breast Cancer

Interventions

• N-803
• PD-L1 t-haNK
• Sacituzumab Govitecan-Hziy
• Cyclophosphamide

Countries

United States